Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tithon Biotech, Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals field. There is currently 1 pending office action under review. This 1 pending office action is assigned to 1 distinct art unit, which suggests a specialized technical focus for the company's current patenting efforts. This concentration in the art unit simplifies the monitoring of the portfolio's progress.
The examination is conducted by 1 distinct examiner, centralizing the decision-making process for the active applications. ZHU, JIANJIAN is listed as the busiest examiner and is currently overseeing 1 busiest examiner pending office action. For practitioners, this means that the 1 distinct examiner has a significant influence over the portfolio's immediate outcomes. The reliance on 1 distinct art unit and 1 distinct examiner indicates a very specific and concentrated prosecution environment. The data reflects a prosecution stage where all current activity is funneled through a specific point of review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002151 | PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002151 | PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS | ZHU, JIANJIAN | 1631 | DP | Final Rejection | — | Pending | Dec 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial